Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company Amarin (NASDAQ: AMRN ) sank 10% today, after announcing plans to sell 21.7 million American depositary shares in a public secondary offering.
So what: The new offering represents around 14% of Amarin's outstanding shares -- with underwriters having a 30-day option to purchase an additional 2% -- so Mr. Market is naturally trying to discount the deal's dilutive effects. Of course, the cash-strapped Amarin said it will use the proceeds to continue the commercial launch of its triglyceride drug Vascepa, so the offering might payoff in the long term.�
Now what: Management will keep seeking approval from the U.S. FDA to market Vascepa as a treatment for patients who have high triglyceride levels and also are taking a statin to control their cholesterol. And as Foolish biotech expert Keith Speights wrote earlier, "There ... appears to be a reasonable chance that the FDA will approve the drug for individuals with high (as opposed to very high) triglyceride levels later this year. Amarin's shares could very well be much higher by year end." So while Amarin remains just too speculative for average Fools, today's double-digit drop -- the stock is now off a whopping 65% from its 52-week highs -- might be an attractive opportunity for biotech-savvy bargain hunters.
5 Best Restaurant Stocks To Watch For 2015: Bayerische Motoren Werke AG (BMW)
Bayerische Motoren Werke AG is a German holding company and automobile manufacturer that focuses on the automobile and motorcycle markets. It divides its activities into the three main segments: Automobiles, Motorcycles and Financial Services. It owns three brands: BMW, MINI and Rolls-Royce. Its BMW automobile range encompasses the 1 Series, including three-door, five-door, coupe and convertible models; the 3 Series, including sedan, touring, coupe and convertible models; the 5 Series, available in sedan and touring models; the 6 Series, available as a coupe or convertible; the 7 Series large sedan; the Z4 roadster and coupe; the sports utility vehicles, X3, X5 and X6 and M models, such as M3, M5 and M6. It also offers cars under the MINI brand and motorcycles under the BMW brand. The Rolls-Royce brand offers three luxury cars, Phantom, Coupe and Ghost. It has producing, assembly, service and sales subsidiaries throughout the world. In January 2013, it sold its Husqvarna brand. Advisors' Opinion:- [By Tom Stoukas]
Deutsche Lufthansa AG (LHA) and Allianz SE (ALV) led airlines and insurers lower, retreating at least 1.5 percent. Bayerische Motoren Werke AG (BMW) slid 1.6 percent. Deutsche Bank AG (DBK) rose after JPMorgan Chase & Co. boosted its recommendation on the shares. Gildemeister AG (GIL) added 3.4 percent after Deutsche Bank upgraded the maker of cutting tools.
- [By Namitha Jagadeesh]
Bayerische Motoren Werke AG (BMW) dropped 0.8 percent to 73.01 euros. The world�� biggest maker of luxury cars said second-quarter earnings before interest and taxes slid 8.8 percent to 2.07 billion euros. Chief Executive Officer Norbert Reithofer said he doesn�� see the European car market rebounding until the second half of 2014.
- [By Bryan Murphy]
While Green Automotive Co. (OTCMKTS:GACR) is certainly no Nissan Motor Co., Ltd. (OTCMKTS:NSANY) or Bayerische Motoren Werke AG (FRA:BMW) (better known as BMW)� in terms of size or notoriety, the two larger car companies certainly seem to be validating the work that GACR is doing. Both Nissan and BMW are betting big on electric vehicles, partly because they want to, and partly because they have to. Either way, Green Automotive is just as capable of tapping into this EV megatrend as its bigger and more established brothers are.
- [By Inyoung Hwang]
Bayerische Motoren Werke AG (BMW) dropped 2.9 percent after the world�� biggest maker of luxury vehicles reported a decrease in third-quarter profit. Siemens AG (SIE) lost 1.3 percent after UBS AG cut its rating on Europe�� largest engineering company. Beiersdorf AG (BEI) rallied 5.3 percent after increasing its full-year sales forecast.
Top 5 Long Term Stocks To Buy For 2014: Alliance Resource Partners L.P.(ARLP)
Alliance Resource Partners, L.P. engages in the production and marketing of coal for utilities and industrial users in the United States. It operates nine underground mining complexes, which offer low, medium, and high-sulfur coal. The company also leases land and operates a coal loading terminal on the Ohio River at Mt. Vernon, Indiana; and purchases and resells coal. In addition, the company provides mine products and services comprising design and installation of underground mine hoists for transporting employees and materials in and out of mines; design of systems for automating and controlling various aspects of industrial and mining environments; and design and sale of mine safety equipment, such as its miner and equipment tracking, and proximity detection systems. Further, it offers ash and scrubber sludge removal, coal yard maintenance, and arranging alternate transportation services. As of December 31, 2010, the company had approximately 697.4 million tons of coal reserves in Illinois, Indiana, Kentucky, Maryland, Pennsylvania, and West Virginia. Alliance Resource Management GP, LLC serves as the general partner of Alliance Resource Partners, L.P. The company was founded in 1971 and is based in Tulsa, Oklahoma.
Advisors' Opinion:- [By Holly LaFon] nce Resources Partners is a coal producer and marketer primarily in the eastern U.S. Its ROA has been increasing since 2008 and increased to 22.5% in 2011 from 21.4% in 2010. The average return on assets for the oil, gas & consumable fuels industry in the trailing 12 months is 24.47%.
In 2011, its total assets increased to $1.7 billion from $1.1 billion in 2010. Its net income increased to $389 million from $321 million.
Factset Research Systems Inc. (FDS)
Factset researches global market trends and develops analytical tools for investors. Of all of GuruFocus��5-star predictable companies, it has the highest return on assets at 27%. ROA has been increasing over the past several years. The average return on assets for the software industry for the trailing 12 months is 13.07%.
In 2011, the company�� total assets increased to $657 million from $645 the prior year. Its net income increased to $171 million from $150.
The All-in-One Screener is a fully customizable stock-searching tool just introduced by GuruFocus. Search for stocks according to your own set of requirements here.
Top 5 Long Term Stocks To Buy For 2014: Intellicell Biosciences Inc (SVFC)
Intellicell Biosciences, Inc., formerly Media Exchange Group, Inc., incorporated on March 8, 1999, is engaged in regenerative medicine company focused on the expanding regenerative medical markets using a process to separate adult autologous vascular cells (AAVC's) from blood vessels in adult adipose (fat) tissue. The Company is also exploring and undertaking, either on its own or in collaboration with a third party, providing a service for the collection, processing and storage of autologous cells for future use. As of December 31, 2011, the Company has developed technologies that allow reproducible separation of stromal vascular fraction (IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors��offices. On June 3, 2011, the Company completed the acquisition of Intellicell Biosciences, Inc. The Company formed a wholly-owned subsidiary, ICBS Research, Inc.
The Company's process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue, which results in the separation AAVC's from the blood vessels in adult adipose (fat) tissue. This AAVC, or stromal vascular fraction (IntelliCells), are removed from the patient at the point of care, and separated at the point of care under the supervision of its certified technicians following current good manufacturing practices (cGMPs) and current good tissue practices (cGTPs), and the cells are then returned to the medical professionals at the point of care for use a patient's own body (autologous treatment), by way of a same-day clinical procedure for homologous use of these cells.
Intellicell Biosciences, Inc., formerly Media Exchange Group, Inc., incorporated on March 8, 1999, is engaged in regenerative medicine company focused on the expanding regenerative medical markets using a process to separate adult autologous vascular cells (AAVC's) from blood vessels in adult adipose (fat) tissue. The Company is also exploring and undertaking, either on ! its own or in collaboration with a third party, providing a service for the collection, processing and storage of autologous cells for future use. As of December 31, 2011, the Company has developed technologies that allow reproducible separation of stromal vascular fraction (IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors��offices. On June 3, 2011, the Company completed the acquisition of Intellicell Biosciences, Inc. The Company formed a wholly-owned subsidiary, ICBS Research, Inc.
The Company's process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue, which results in the separation AAVC's from the blood vessels in adult adipose (fat) tissue. This AAVC, or stromal vascular fraction (IntelliCells), are removed from the patient at the point of care, and separated at the point of care under the supervision of its certified technicians following current good manufacturing practices (cGMPs) and current good tissue practices (cGTPs), and the cells are then returned to the medical professionals at the point of care for use a patient's own body (autologous treatment), by way of a same-day clinical procedure for homologous use of these cells.
The Company competes with Cytori Therapeutics, Stem Cell Assurance, Inc., Osiris, Aastrom Biosciences, Aldagen, BioTime, Baxter International, Celgene, Geron, Harvest Technologies, Mesoblast, Regenexx, NeoStem, X-Cell Center, Stem Cells, Athersys, and Tissue Genesis, Life Technologies, Asterand, pacific biosciences of california inc. and AllCells, LLC.
Advisors' Opinion:- [By Bryan Murphy]
To say that shares of IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) has been disappointing since 2011 would be an understatement. SVFC has been an outright disaster since 2011, falling from a peak of $19.00 to a low of, well, just a few pennies as of late last year. In fact, there are those who are understandably wondering how the company is still alive, only producing about a half a million dollars in revenue in 2012, and then dialing that figure back down to nothing for the last few quarters. Yet, there's just something about a company that refuses to go away.... something compelling now.
Top 5 Long Term Stocks To Buy For 2014: Tumi Holdings Inc (TUMI)
Tumi Holdings, Inc. (Tumi), incorporated in September 2004, offers a range of travel and business products and accessories in various categories. The Company designs its products for, and markets its products to, professionals, travelers and individuals. As of December 31, 2011, the Company distributed its products worldwide in over 70 countries through approximately 1,600 points of distribution. The Company sells its products worldwide to consumers through both direct and indirect channels and manages its business through four operating segments: Direct-to-Consumer North America, Direct-to-Consumer International, Indirect-to-Consumer North America and Indirect-to-Consumer International.
Tumi utilizes an array of channels, including retail, wholesale and e-commerce. The Company�� retail stores are located in retail venues worldwide, including New York, San Francisco, Chicago, Paris, London, Rome, Tokyo, Munich, Moscow, Milan and Barcelona. The Company designs its products in its United States design studios. The Company sells its products directly to consumers through a worldwide network of approximately 100 company-owned locations, consisting of full-price stores located in retail malls or street venues, outlet stores in outlet malls and its e-commerce Websites. During the year ended December 31, 2011, Direct-to-Consumer sales consisted approximately 48% of its net sales.
The Company sells its products indirectly to consumers through various channels that include partner stores (wholesale accounts operated by local distributors or retailers that carry only Tumi products), its worldwide wholesale distribution network of specialty luggage retailers, department stores and business-to-business channels, retail concessions within department stores and third-party e-commerce sites, such as Amazon.com, Zappos.com. Indirect-to-Consumer sales consisted of approximately 52% of its net sales during 2011. Tumi offers travel and business products, as well as accessories. Travel produc! ts include wheeled and soft carry-on luggage, garment bags, totes, duffels, wheeled packing cases and travel kits. Business products include business cases, day bags and totes. Its accessories include agendas and planners, passport cases, umbrellas and travel accessories, such as electric current adapters, key fobs, packing accessories, toiletry kits and foldable travel totes. Its accessories also include belts, outerwear and sunglasses and eyewear.
Direct-to-Consumer North America
The Company sells its products directly to consumers through a network of 83 company-owned retail stores consisting of full-price stores and outlet stores located in retail malls or street venues. It also sells its product directly to consumers through its e-commerce Website.
Direct-to-Consumer International
As of December 31, 2011, the Company sold directly to consumers through a network of 14 company-owned full-price and outlet stores in street venues and select malls in international locations. It also sells its products directly to consumers through its two international e-commerce Websites.
Indirect-to-Consumer North America
As of December 31, 2011, the Company sold to wholesale customers in North America through approximately 700 doors, including specialty luggage retailers, department stores and business-to-business channels. Many of its wholesale customers also operate their own e-commerce Websites through which it sells. The Company�� products are also sold in partner stores operated by local distributors or retailers that carry only Tumi products.
Indirect-to-Consumer International
The Company sells its products to wholesale customers through approximately 800 doors, approximately 59% of which are in the Europe, Middle East and Africa region, 39% of which are in the Asia-Pacific region, and 2% of which are in the Central and South America region. It has distribution channels in Australia, China, Europe, Hong Kon! g, the Mi! ddle East, South Africa, South Korea, Southeast Asia and Taiwan. Its products are also sold in partner stores operated by local distributors or retailers that carry only Tumi products. The Company also operates concessions in department stores throughout Europe and the Middle East. Many of its wholesale customers also operate their own e-commerce Websites through which they sell its products.
Tumi competes with Rimowa, Samsonite, Bally, Burberry, Dunhill, Ferragamo, Gucci, Louis Vuitton, Montblanc, Porsche, Prada, Victorinox, Briggs and Riley, Mandarina Duck, Piquadro, Porter, Ace Brand, and Coach.
Advisors' Opinion:- [By Michael Lewis]
Luxury luggage brand Tumi (NYSE: TUMI ) , a little more than one year since its IPO, has failed to achieve much in the way of capital appreciation. The company came out of the gates with a rich valuation, heavily influenced by the then-recent success of other high-line brands such as Michael Kors. Tumi is growing, and will continue to grow -- much of its performance (or lack thereof) in the market has been the typical story of overvaluation and overhype. In the just-released earnings, there is plenty of evidence of a fundamentally strong company with a long runway for growth, even if Wall Street analysts were expecting a little more. With a long-term mind-set, is Tumi a good stock?
No comments:
Post a Comment